奥拉帕利治疗后进展的卵巢癌经尼拉帕利行细胞减灭术成功治疗：一例报告。
Successful Management of Ovarian Cancer Progressing on Olaparib by Niraparib Following Cytoreduction: A Case Report.
机构信息
Department of Obstetrics and Gynecology, Fukushima Medical University School of Medicine, Fukushima, Japan;
Department of Regional Gynecologic Oncology, Fukushima Medical University School of Medicine, Fukushima, Japan.
出版信息
In Vivo. 2024 Mar-Apr;38(2):958-962. doi: 10.21873/invivo.13527.
BACKGROUND
Polyadenosine 5'-diphosphoribose polymerase inhibitors (PARP-Is) are novel, effective agents for treating newly diagnosed epithelial ovarian cancer (EOC). However, the effect of PARP-I on the progression of recurrent EOC has not yet been determined. In particular, there is limited evidence regarding retreatment with PARP-I for recurrent EOC that has progressed on PARP-I in the short term.
CASE REPORT
A 69-year-old woman with a BRCA1 mutated EOC relapsed five months after starting olaparib maintenance following neoadjuvant chemotherapy and interval debulking surgery. Although the platinum-free interval was within six months, secondary cytoreductive surgery was performed because the tumor was locoregional. Following two cycles of weekly nedaplatin, niraparib induced a complete response, and the patient maintained a progression-free status for 15 months.
CONCLUSION
Even with short-term progression on PARP-I, local control combined with different platinum agents and PARP-I can be used to achieve good responses.
背景
聚腺苷二磷酸核糖聚合酶抑制剂（PARP-Is）是治疗新诊断的上皮性卵巢癌（EOC）的新型有效药物。然而，PARP-I 对复发性 EOC 的进展的影响尚未确定。特别是，对于在短期内因 PARP-I 进展而复发的 EOC 再次使用 PARP-I 治疗的证据有限。
病例报告
一名 69 岁的 BRCA1 突变型 EOC 女性，在新辅助化疗和间隔减瘤手术后开始奥拉帕利维持治疗五个月后复发。尽管无铂间期在六个月内，但由于肿瘤位于局部区域，因此进行了二次细胞减灭性手术。在接受两个周期的每周奈达铂治疗后，尼拉帕利诱导完全缓解，患者无进展状态持续了 15 个月。
结论
即使在 PARP-I 短期内进展，局部控制联合不同的铂类药物和 PARP-I 也可以实现良好的反应。
Zotero 插件